Additionally, the safety of soluble TRAIL was demonstrated for therapy, in vivo, but also showed that the application of TRAIL decreases tumor progression by suppressing tumor xenografts 36, 37 and supports the consideration that patients with reduced TRAIL expression may benefit from therapeutic agents with TRAIL‐inducing effects 38, 39, 40. This evidence concerns the gene TNFSF10 and neoplasm.